Pulmonary Arterial Hypertension Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Pulmonary Arterial Hypertension stocks.

Pulmonary Arterial Hypertension Stocks Recent News

Date Stock Title
May 3 LLY Amazon Stock Is on a Roll. Here’s Why It’s on This Firm’s ‘Best Ideas List.’
May 3 PFE Amgen's peek at its GLP-1 drug trial results heightens competition in obesity market
May 3 LLY Amgen's peek at its GLP-1 drug trial results heightens competition in obesity market
May 3 LLY Eli Lilly Remains Expensive Here - Minimal Margin Of Safety
May 3 LLY Analyst unveils Amgen stock price target after weight-loss drug data
May 3 UTHR 30 Most Profitable Companies with Highest Margins in the World
May 3 KROS Keros Therapeutics files automatic mixed shelf
May 3 PFE Vanguard Health Care Fund's Strategic Moves in Q1 2024: A Focus on Pfizer Inc
May 3 LLY Amgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update
May 3 LLY Weight-loss drug competition heats up. Is Wegovy in trouble?
May 3 LLY Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
May 3 PFE Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
May 3 LLY Amgen Knocks Novo Nordisk's Ozempic Stock Rally. Its Stock Is Flying.
May 3 PFE Here's Why Pfizer (PFE) is a Strong Momentum Stock
May 3 LLY US STOCKS-Wall St set to open sharply higher on soft jobs data
May 3 LLY Amgen shares soar as executives outline obesity drug push
May 3 LLY US STOCKS-Futures rise on Apple, Amgen boost; jobs data awaited
May 3 LLY How the CFOs of Eli Lilly and Novo Nordisk are coping with ‘unprecedented demand’ for weight-loss drugs
May 3 PFE Q1 2024 Cardiff Oncology Inc Earnings Call
May 3 PFE NHS to provide Pfizer’s Voxelotor to treat sickle cell disease
Pulmonary Arterial Hypertension

Pulmonary hypertension (PH or PHTN) is a condition of increased blood pressure within the arteries of the lungs. Symptoms include shortness of breath, syncope, tiredness, chest pain, swelling of the legs, and a fast heartbeat. The condition may make it difficult to exercise. Onset is typically gradual.The cause is often unknown. Risk factors include a family history, prior blood clots in the lungs, HIV/AIDS, sickle cell disease, cocaine use, COPD, sleep apnea, living at high altitudes, and problems with the mitral valve. The underlying mechanism typically involves inflammation of the arteries in the lungs. Diagnosis involves first ruling out other potential causes.There is no cure. Treatment depends on the type of disease. A number of supportive measures such as oxygen therapy, diuretics, and medications to inhibit clotting may be used. Medications specifically for the condition include epoprostenol, treprostinil, iloprost, bosentan, ambrisentan, macitentan, and sildenafil. A lung transplant may be an option in certain cases.While the exact frequency of the condition is unknown, it is estimated that about 1,000 new cases occur a year in the United States. Females are more often affected than males. Onset is typically between 20 and 60 years of age. It was first identified by Ernst von Romberg in 1891.

Browse All Tags